Administration of small doses of radiolabeled phencyclidine hydrochloride (PCP X HCl) to normal volunteers has resulted in basic information on the disposition of PCP in humans. The drug and its metabolites were excreted mainly in the urine whether it was given orally or i.v. (73 +/- 4% of dose was recovered in urine after i.v. administration of 1 mg), with very little fecal excretion (3-5%) and some excretion in sweat. Oral bioavailability was 72 +/- 8%. Major metabolic pathways found involved hydroxylation of the cyclohexane and piperidine rings followed by conjugation. Oxidation to an aminopentanoic acid also occurred. PCP and phenylcyclohexene were inhaled when PCP was smoked. For PCP the weighted mean apparent terminal rate constant (beta) was 0.0395 +/- 0.0008 h-1 for 16 subjects, equivalent to a half-life of 17.6 h, but 2 subjects had half-lives of over 2 days. The volume of distribution (Vd, beta) was 6.2 +/- 0.3 liters/kg. At usual urinary pH, PCP excretion represented less than 10% of total clearance, but marked lowering of urinary pH can significantly increase the contribution of renal clearance to overall clearance.
Download full-text PDF |
Source |
---|
Cardiovasc Ther
January 2025
College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan-si, Gyeonggi-do, Republic of Korea.
Dose adjustments of direct-acting oral anticoagulants (DOACs) for atrial fibrillation are based on pivotal clinical trials assessing their effectiveness and safety in controlled settings. However, the appropriateness of these dosing strategies in real-world practice is uncertain. The purpose of this study is to compare the effectiveness and safety of dose-specific DOACs with those of warfarin.
View Article and Find Full Text PDFTher Clin Risk Manag
January 2025
Departments of Medicine and Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA.
Pulmonary arterial hypertension (PAH) is a rare and potentially fatal condition characterized by progressive increases in blood pressure in the arteries of the lungs. Oral selexipag, approved by the Food and Drug Administration (FDA) in 2015 for the treatment of PAH, targets prostacyclin receptors on pulmonary arterial vascular smooth muscle and endothelial cells to improve blood flow through the lungs and reduce pulmonary vascular resistance. Oral selexipag is effective, but may be discontinued due to factors like side effects, emergency conditions, or inability to take oral medication, potentially leading to severe adverse events, such as rebound pulmonary hypertension and right heart failure.
View Article and Find Full Text PDFAJR Am J Roentgenol
January 2025
Department of Radiology, Division of Breast Imaging and Intervention, Mayo Clinic, Phoenix, AZ.
Contrast-enhanced mammography (CEM) is growing in clinical use due to its increased sensitivity and specificity compared to full-field digital mammography (FFDM) and/or digital breast tomosynthesis (DBT), particularly in patients with dense breasts. To perform an intraindividual comparison of MGD between FFDM, DBT, a combination protocol using both FFDM and DBT (combined FFDM-DBT), and CEM, in patients undergoing breast cancer screening. This retrospective study included 389 women (median age, 57.
View Article and Find Full Text PDFRadiat Environ Biophys
January 2025
Laboratory of Health Sciences and Technologies, Higher Institute of Health Sciences, Hassan First University, Settat, Morocco.
This study assesses radiation doses in multi-slice computed tomography (CT) using epoxy resin and PMMA phantoms, focusing on the relationship between TAR (tissue air ratio) and kilovoltage peak (kVp). The research was conducted using a Hitachi Supria 16-slice CT scanner. An epoxy resin phantom was fabricated from commercially available materials, to simulate human tissue.
View Article and Find Full Text PDFHIV Med
January 2025
Division of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, Canada.
Objective: To measure concentrations of tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) among individuals taking tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) or tenofovir alafenamide plus emtricitabine (TAF/FTC) who were scheduled to undergo or had already undergone bariatric surgery.
Methods: We enrolled pre-exposure prophylaxis (PrEP) users attending clinics in Toronto or Ottawa who were undergoing or had undergone bariatric surgery. After participants completed a minimum of 7 days of consecutive PrEP dosing, we collected DBS samples immediately before they administered their next daily dose of PrEP.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!